Target identification in solid tumors can help enable therapeutic development against indications of high unmet need and across a wide patient population. Checkpoint therapy has shown that CD8+ T cells are responsible for driving patient responses, and yet the specificities of these T cells cannot be directly determined in an unbiased manner. We have developed a high-throughput platform to directly determine the specificities of clonally enriched and shared patient T cell responses. This information can be used to link clinical responses, immune biomarkers, and T cell specificities to evaluate the most promising shared targets in solid tumors and understand the mechanism of action of current anticancer drugs. These targets can be used to develop T cell therapies or other therapeutic modalities that can be used to improve the outcomes of clinical treatment in an array of solid tumor indications.
